Hepatitis C Virus Infection in Zliten Dialysis Centre, Libya

Wanis M. Wanis; Mutwakil G. Ahmed; Ali M. Abdalaziz; Almahdi W. Alamen

doi:10.51984/n2fk7e19

Authors

Wanis M. Wanis Department of Medicine, Faculty of Medicine, University of Sebha, Sebha, Libya
Mutwakil G. Ahmed Department of Medicine, Faculty of Medicine, University of Sebha, Sebha, Libya
Ali M. Abdalaziz Department of Internal Medicine, Zliten Teaching Hospital, Zliten, Libya
Almahdi W. Alamen Department of Medicine, Faculty of Medicine, University of Sebha, Sebha, Libya

DOI:

https://doi.org/10.51984/n2fk7e19

Keywords:

Hepatitis C virus, Haemodialysis, Prevalence, Seroconversion, Infection control, Zliten

Abstract

Hepatitis C virus is a major health problem in haemodialysis units worldwide. The present study revealed that the prevalence of hepatitis C virus (HCV) infection in Zliten dialysis center is 62%. The incidence of HCV sero-conversion in Zliten was 51.3% in the years 2002-2004. The most important risk factors contributing to this high prevalence rate could be the failure to adhere to the universal precautions, prolonged duration of dialysis and dialysis in other dialysis centers.

The prevalence of HCV in this dialysis centre is high and reflects the need for a well-designed infection control policy. The control program should emphasize that dialysis therapy must be delivered using universal precautions to avoid contact with blood and blood products. Intensive efforts to prevent cross-infection should, therefore, be directed towards sterilization of dialysis consoles, liberal use of disposable materials and a greater awareness of medical and paramedical personnel along a supplementary midday sterilization of dialysis monitors and personal disposable dressing kits.

Downloads

Download data is not yet available.

References

Dienstag JL. and Issetbacher KJ. Acute viral hepatitis. In Dennis I. Kasper, Eugene Braunwald, Anthony S. Fanci, Dan L. Longo, Stephen L. Hanser, J. Larry Jameson; (eds); Harison's Principles of Internal Medicine, McGraw-Hill, New York, 2005.

World Health Organization. Hepatitis C: Global prevalence. Wkly Epidemiol Rec. 1977; 72: 341-4.

Poynard T. Hepatitis C and B Management and Treatment. Taylor and Francis, London. 2005.

Darby Sc., Ewatt DW., Giangrande PL., et al. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet, 1997; 350: 1425-31.

El Serag HB., Mason A. A rising incidence of hepatocelluler carcinoma in the United States. N Engl J Med. 1999; 34: 745-50.

Deuffic S., Buffat L., Poynard T., and Valleron AJ. Modelling the hepatitis C virus epidemic in France Hepatology, 1999; 29: 1596-601.

Deuffic S., Poynard T., and Valler AJ. Correlation between HCV prevalence and hepatocellulr carcinoma mortality in Europe. J viral Hepat, 1999; 6: 411-13.

Alter MJ., Kruszon-Moran D., Nainan OV., et al. The prevalence of hepatitis C virus infection in the United States, 1988-1994. N Enfl J Med. 1999; 341: 556-62.

Fabrizi F., Poordad F., and Marti P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology, 2002; 36: 3-10.

Bruchfeld A., Stahle L., Andersson J., and Schvarez R. Ribavirim treatment in dialysis patients with chronic hepatitis C infection – a pilot study. J Viral Hepat. 2001; 8: 278-92.

Kiyad AS., and Yusuf E. HCV infection in hemodialysis patients in Jordan. Saudi M. J. 2003; 24: 137.

Salma M. Sulaiman. Prevalence of HCV infection in hemodialysis patients in Sudan. Saudi M. J. 2003; 24: 138.

Mohamed AD., Mohammed AG., Aisha MD. Prevalence of HCV antibody among different population of relative risk. Saudi M. J. 2005; 4: 150.

Mutwakil G. Ahmed, Mohamed A Busefi and Ibrahim A. Shnaf. Hepatitis C virus infection in hemodialysis patients in Sebha. Sebha M. J. 2002; 2: 15.

Afatah Z. Hanan. Prevalence of HBV and HCV in hemodialysis patients in Benghazi. Sebha M. J. 2002; 3: 35.

Forn X. Frandez L., Pons M. et al. Incidence and risk factors of hepatitis C virus infection in a hemodialysis unit. Nephrol Dial transplant, 1997; 12: 736.

Cristina G., Piazza V., Efficace E. et al. A survey of hepatitis C in hemodialysis patients over a 7-years follow up. Nephrol Dial Transplant. 1997; 12: 2208.

Fakunle YM., and Al Mofareh M. Prevalence of antibodies to HCV in haemodialysis patients in Riyadh. Ann Saudi Med. 1991; 11: 504.

Morales J., Munoz MA., Castellano G., et al. Impact of hepatitis C in long functioning renal transplants. Transplant Proc. 1993; 25: 1450.

Jadoul M., Corna C., and Van Ypersele C. Incidence and risk factors for hepatitis C sero-conversion in haemodialysis: a prospective study. Kid Int. 1993; 44: 1322.

Stuyver L., Claeys H., Wyseur A., et al. Hepatitis C virus in a haemodialysis unit: Molecular evidence for nosocomial transmission. Kid. Int. 1996; 49: 889.

Yasa T., Ishikawa G., Manabe S., et al. The particle size of hepatitis C virus estimated by filtration through microporsus regenerated cellulose fibre. . Gen. Virol. 1991;72: 2021.

Caramello C., Navas S., Alnerta M., et al. Evidence against transmission of hepatitis C virus though haemodialysis ultrafilterate and peritoneal fluid. Nephron. 1994; 66: 740.

Centers for Disease Control: updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendation for posture-posure prophylauis. MMWR MOrb Mortal. Wkly Rep. 2001; 50: 1-52.

Secretary of Health and Environment. Public health guidelines for control of hospital cross-infection. Tripoli. 2005.

Abbotts HCV Enzyme linked Immuno Assay-Second generation Kits. Abbotts. Germany, 2002.

American Association of Blood Banks Standards for Blood Banks and transfusion Services. Bethseda. 1993.

Jacobs DS., Oxley DK., and De Mott WR. Lexi-Comps Laboratory Test Handbook. Lexi-Comps Hudson. 2002.

Yassin I. Shahat. Hepatitis C virus infection in dialysis patients in the United Arab Emirates. Saudi Med. J. 2003;24: 139.

Ozyilkan E., Simsek H., Lizunalimoglu B., et al. Interferon treatment of Chronic active hepatitis in patients with end-stage chronic renal failure. Nephron. 1995; 71: 156.